AstraZeneca PLC (AZNCF)
155.26
-0.46
(-0.30%)
USD |
OTCM |
May 17, 16:00
AstraZeneca Enterprise Value: 266.03B for May 17, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| May 17, 2024 | 266.03B |
| May 16, 2024 | 266.74B |
| May 15, 2024 | 262.53B |
| May 14, 2024 | 262.34B |
| May 13, 2024 | 266.93B |
| May 10, 2024 | 267.19B |
| May 09, 2024 | 261.49B |
| May 08, 2024 | 261.60B |
| May 07, 2024 | 252.68B |
| May 06, 2024 | 255.13B |
| May 03, 2024 | 256.71B |
| May 02, 2024 | 263.27B |
| May 01, 2024 | 259.46B |
| April 30, 2024 | 259.43B |
| April 29, 2024 | 252.06B |
| April 26, 2024 | 250.28B |
| April 25, 2024 | 251.76B |
| April 24, 2024 | 235.17B |
| April 23, 2024 | 242.84B |
| April 22, 2024 | 240.41B |
| April 19, 2024 | 236.48B |
| April 18, 2024 | 239.65B |
| April 17, 2024 | 242.61B |
| April 16, 2024 | 235.10B |
| April 15, 2024 | 236.08B |
| Date | Value |
|---|---|
| April 12, 2024 | 240.64B |
| April 11, 2024 | 236.95B |
| April 10, 2024 | 236.56B |
| April 09, 2024 | 234.25B |
| April 08, 2024 | 237.17B |
| April 05, 2024 | 231.86B |
| April 04, 2024 | 238.27B |
| April 03, 2024 | 229.61B |
| April 02, 2024 | 229.45B |
| April 01, 2024 | 235.86B |
| March 31, 2024 | 237.66B |
| March 28, 2024 | 233.97B |
| March 27, 2024 | 230.48B |
| March 26, 2024 | 224.04B |
| March 25, 2024 | 228.18B |
| March 22, 2024 | 226.86B |
| March 21, 2024 | 224.73B |
| March 20, 2024 | 224.72B |
| March 19, 2024 | 223.09B |
| March 18, 2024 | 224.59B |
| March 15, 2024 | 225.38B |
| March 14, 2024 | 229.58B |
| March 13, 2024 | 233.11B |
| March 12, 2024 | 228.33B |
| March 11, 2024 | 228.42B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
112.53B
Minimum
Mar 13 2020
267.19B
Maximum
May 10 2024
188.86B
Average
196.56B
Median
Enterprise Value Benchmarks
| GSK PLC | 108.21B |
| Adaptimmune Therapeutics PLC | 140.02M |
| Biodexa Pharmaceuticals Plc | -2.388M |
| Verona Pharma PLC | 847.73M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | 2.179B |
| Revenue (Quarterly) | 12.68B |
| Total Expenses (Quarterly) | 9.564B |
| EPS Diluted (Quarterly) | 1.40 |
| Gross Profit Margin (Quarterly) | 82.51% |
| Profit Margin (Quarterly) | 17.19% |
| Earnings Yield | 2.62% |
| Operating Earnings Yield | 3.93% |
| Normalized Earnings Yield | 2.864 |